Atara Biotherapeutics IncNASDAQ:ATRA
- LAST PRICE10.6100
- TODAY'S CHANGE (%)-0.0700 (-0.6554%)
- Bid / Lots10.3000/ 15
- Ask / Lots11.5400/ 2
- Open / Previous Close10.7300 / 10.6800
- Day Range
- 52 Week Range
- Volume81,183
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ATRA |
|---|---|---|
| 09:32 ET | 392 | 10.73 |
| 09:33 ET | 191 | 10.6862 |
| 09:35 ET | 546 | 10.6 |
| 09:42 ET | 2950 | 10.29 |
| 09:46 ET | 600 | 10.21 |
| 09:48 ET | 1074 | 10.37 |
| 09:50 ET | 630 | 10.355 |
| 09:51 ET | 100 | 10.355 |
| 09:53 ET | 500 | 10.355 |
| 10:06 ET | 200 | 10.205 |
| 10:09 ET | 5447 | 10.11 |
| 10:11 ET | 100 | 10.11 |
| 10:13 ET | 350 | 10.1 |
| 10:18 ET | 100 | 10.2 |
| 10:20 ET | 1003 | 10.26 |
| 10:27 ET | 2412 | 10.19 |
| 10:29 ET | 100 | 10.23 |
| 10:31 ET | 3658 | 10.03 |
| 10:33 ET | 757 | 10.04 |
| 10:36 ET | 1200 | 10.03 |
| 10:40 ET | 400 | 10.15 |
| 10:42 ET | 500 | 10.2899 |
| 10:49 ET | 100 | 10.15 |
| 11:03 ET | 100 | 10.26 |
| 11:05 ET | 100 | 10.26 |
| 11:07 ET | 100 | 10.26 |
| 11:20 ET | 1264 | 10.33 |
| 11:30 ET | 1000 | 10.345 |
| 11:32 ET | 349 | 10.15 |
| 11:36 ET | 100 | 10.195 |
| 11:39 ET | 406 | 10.195 |
| 11:56 ET | 150 | 10.121 |
| 11:57 ET | 100 | 10.1 |
| 12:03 ET | 2228 | 10.05 |
| 12:06 ET | 995 | 10.03 |
| 12:08 ET | 100 | 10.04 |
| 12:10 ET | 100 | 10.04 |
| 12:14 ET | 200 | 10.03 |
| 12:17 ET | 100 | 10.05 |
| 12:19 ET | 100 | 10.1 |
| 12:21 ET | 100 | 10.095 |
| 12:24 ET | 500 | 10.15 |
| 12:26 ET | 900 | 10.19 |
| 12:37 ET | 3305 | 10.3199 |
| 12:44 ET | 100 | 10.2 |
| 12:48 ET | 395 | 10.3 |
| 12:57 ET | 200 | 10.3 |
| 01:04 ET | 100 | 10.31 |
| 01:08 ET | 200 | 10.418 |
| 01:38 ET | 300 | 10.31 |
| 01:47 ET | 100 | 10.355 |
| 01:49 ET | 3456 | 10.21 |
| 02:02 ET | 100 | 10.27 |
| 02:05 ET | 1400 | 10.32 |
| 02:21 ET | 400 | 10.305 |
| 02:23 ET | 1740 | 10.24 |
| 02:45 ET | 300 | 10.33 |
| 02:48 ET | 1015 | 10.41 |
| 02:50 ET | 259 | 10.395 |
| 03:01 ET | 100 | 10.35 |
| 03:10 ET | 292 | 10.32 |
| 03:15 ET | 400 | 10.33 |
| 03:17 ET | 600 | 10.43 |
| 03:21 ET | 7507 | 10.53 |
| 03:24 ET | 100 | 10.53 |
| 03:26 ET | 100 | 10.53 |
| 03:28 ET | 100 | 10.53 |
| 03:30 ET | 100 | 10.53 |
| 03:32 ET | 320 | 10.4688 |
| 03:37 ET | 100 | 10.47 |
| 03:44 ET | 100 | 10.535 |
| 03:51 ET | 200 | 10.47 |
| 03:53 ET | 2150 | 10.48 |
| 03:55 ET | 1200 | 10.65 |
| 03:57 ET | 1764 | 10.62 |
| 04:00 ET | 1974 | 10.61 |
Nov 13, 2024
Atara Biotherapeutics to Participate at the Stifel 2024 Healthcare Conference, from 4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
4:01PM ET on Wednesday Nov 13, 2024 by Dow Jones
Nov 12, 2024
Atara Biotherapeutics Announces Third Quarter 2024 Financial Results and Operational Progress, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones*DJ Atara Biotherapeutics 3Q Loss/Shr $2.93 >ATRA, from 4:01PM ET on Tuesday Nov 12, 2024 by Dow Jones
4:01PM ET on Tuesday Nov 12, 2024 by Dow JonesSidoti Events, LLC's Virtual November Micro-Cap Conference, from 8:32AM ET on Tuesday Nov 12, 2024 by Dow Jones
8:32AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 5, 2024
Press Release: Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024, from 4:03PM ET on Tuesday Nov 05, 2024 by Dow Jones
4:03PM ET on Tuesday Nov 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Atara Biotherapeutics Inc | 60.5M | -0.4x | --- |
Affimed NV | 41.4M | -0.6x | --- |
Clearside Biomedical Inc | 79.6M | -2.3x | --- |
Kronos Bio Inc | 51.9M | -0.6x | --- |
Cue Biopharma Inc | 65.6M | -1.1x | --- |
Collplant Biotechnologies Ltd | 48.5M | -2.7x | --- |
Company Information
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 is in Phase 1 development is being developed as a potential product intended to target B-cell malignancies and autoimmune diseases, based on a next generation 1XX co-stimulatory domain and the innate advantages of EBV T cells as the foundation for an allogeneic CAR T platform.
Contact Information
- Headquarters
- 2380 Conejo Spectrum St, Suite 200THOUSAND OAKS, CA, United States 91320
- Phone
- 805-623-4244
- Fax
- 302-636-5454
Executives
- Chairman of the Board
- Pascal Touchon
- President, Chief Executive Officer, Director
- Anhco Nguyen
- Chief Financial Officer, Chief Operating Officer
- Eric Hyllengren
- Executive Vice President - Global Head Regulatory Affairs and Quality
- Jill Henrich
- Lead Independent Director
- Carol Gallagher
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $60.1M |
|---|---|
Revenue (TTM) | $100.4M |
Shares Outstanding | 5.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-26.44 |
Book Value | $-23.31 |
P/E Ratio | -0.4x |
Price/Sales (TTM) | 0.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -130.62% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
